RVNC News and Press, Revance Therapeutics Inc. From 11/04/19

Revance Therapeutics, Inc. (RVNC) Q3 2019 Earnings Conference Call November 4, 2019 16:30 ET Company Participants Jeanie Herbert - Senior Director of IR & Corporate Communications Mark Foley - President & CEO Tobin Schilke - CFO & Principal Accounting Officer Abhay ...

Revance Therapeutics (NASDAQ: RVNC ): Q3 GAAP EPS of -$0.96 beats by $0.02 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Conference call and webcast today at 4:30 p.m. ET – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the quarter ended Septemb...

- DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder - - Topline data expected in second half of 2020 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company...

- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, tod...

Cellectis S.A. (NASDAQ: CLLS ) resumed with Buy rating and $28 (151% upside) price target at Guggenheim. Shares up  3%  premarket. More news on: Cellectis S.A., Gossamer Bio, Inc., Health Catalyst, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release third quarter...

- Revance’s long-acting neuromodulator DAXI will be featured in three abstracts and three oral presentations at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new i...

Monday was a relatively quiet day on Wall Street, as investors largely allowed major benchmarks to tread water. Trade negotiations didn't deliver the home run victory that many had hoped to see, and that kept market participants from bidding up indexes further from Friday's gains. Yet some indiv...

Revance Therapeutics ( RVNC +2.7% ) appoints Mark Foley as President and CEO, replacing Dan Browne, who resigned due to a misjudgment in handling an employee matter. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Read more ...